# FDA Approves Generic Oxcarbazepine Oral Formulation by Zydus Lifesciences Zydus Lifesciences Limited has received FDA approval for a generic version of oxcarbazepine, an anticonvulsant medication, potentially expanding treatment access and creating competitive pricing pressure in the seizure disorder and neuropathic pain markets. The approval of ANDA 211747 allows Zydus to capitalize on the substantial patient population requiring oxcarbazepine therapy while intensifying competition among generic manufacturers in this established therapeutic category.